ArriVent BioPharma

AVBP

Market cap $1.31B

Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and potentially longer progression-free survival compared with the current standard of care. If the drug delivers PFS above ~10 months with statistical significance, Firmonertinib could capture meaningful market share thanks to its oral monotherapy profile and potentially better safety relative to Rybrevant. With $312 million cash (runway to Q3 2027), the valuation appears asymmetric relative. We remain buyers.

NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California April 17-22.

The average of price targets set by Wall Street analysts indicates a potential upside of 70.4% in ArriVent BioPharma, Inc. (AVBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here is how ArriVent BioPharma, Inc. (AVBP) and Ocugen (OCGN) have performed compared to their sector so far this year.

NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2025, and highlighted recent Company progress.

ArriVent BioPharma (AVBP) is a cautious BUY, driven by furmonertinib's late-stage potential in uncommon EGFR-mutant NSCLC and a conservative valuation approach. AVBP's strategy targets niche EGFR mutations—exon 20 insertions, PACC, and others—where competition is less entrenched and regulatory pathways are more navigable. Furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials, supporting risk-adjusted U.S. revenue estimates of $600M–$900M annually.

ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib's near-term clinical catalysts and significant de-risking from Shanghai Allist Pharmaceuticals commercialization. Firmonertinib has continued to deliver encouraging efficacy with a tolerable safety profile across treated patients. Under conservative assumptions, there is an asymmetric valuation setup.